FDA OKs wider use of Almirall’s actinic keratosis drug

With actinic keratosis diagnoses on the rise, there is some good news for patients with the FDA approval of expanded use of Almirall’s topical therapy Klisyri.

First approved in 2020, first-in-class microtubule inhibitor Klisyri (tirbanibulin 1%) reached the market in early 2021, joining a short list of therapies in the US that are available for AK, which is a major public health concern as it can be a precursor to skin cancer.